Akeso Announces Global First-in-Class Trispecific Antibody AK150 Enters Clinical Trials: A Triple-Target Approach to Overcome Immunotherapy Resistance

Core Viewpoint - Akeso, Inc. has announced that its first-in-class trispecific antibody, AK150, has received IND clearance for clinical trials targeting advanced solid tumors, marking a significant advancement in immunotherapy [1] Company Overview - Akeso, Inc. is a leading biopharmaceutical company focused on the research, development, manufacturing, and commercialization of innovative biological medicines, with a robust R&D ecosystem centered on its proprietary Tetrabody platform [1] - The company has over 50 innovative assets in its pipeline, with 27 candidates currently in clinical trials, including 15 bispecific/multispecific antibodies and bispecific ADCs [1] Product Details - AK150 is the only trispecific antibody targeting ILT2, ILT4, and CSF1R globally, designed to overcome immunotherapy resistance by addressing the immunosuppressive tumor microenvironment [1] - The antibody works by depleting immunosuppressive myeloid cells and activating CD8+ T cells and NK cells, enhancing the anti-tumor immune response [1] Clinical Significance - AK150 aims to improve anti-tumor efficacy, particularly for "cold tumors," by converting them into "hot tumors" through a multi-target approach [1] - Preclinical studies have shown that AK150 exhibits dose-dependent tumor inhibition across all tested dosage groups, indicating its potential effectiveness [1]